The test validation trial resulted in CyPath Lung specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer.
Read More
Idylla reduced EGFR mutation testing turnaround time by more than a week versus reference methods for patients with NSCLC.
Read More
Israeli laboratories are approved to use molecular profiling assays for NSCLC patients using Thermo Fisher Scientific’s Oncomine Comprehensive Assay Plus.
Read More
Roche’s algorithm provides automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis.
Read More
The Early Detection for Cancer of the Lung Scotland trial is believed to be the world’s largest trial for the detection of lung cancer using biomarkers.
Read More